文献速递自身免疫性与大疱性皮肤病

大疱性类天疱疮患者的死亡率和预后因素:一项意大利回顾性多中心研究

Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-09-10

该意大利多中心回顾性研究纳入2005至2020年12个中心诊断的572例大疱性类天疱疮患者,粗死亡率为20.6%,年发病死亡率为5.9×100人年;多因素模型显示年龄>78岁、多病共存、抗BP180>72 U/mL或抗BP230>3 U/mL与死亡风险显著升高相关,预测准确度(Harrel指数)为77%。

要点

  • 572例大疱性类天疱疮患者粗死亡率为20.6%,年发病死亡率为5.9×100人年。
  • 1、3、5、10年死亡率分别为3.2%、18.2%、27.4%、51.9%。
  • 年龄>78岁、多病共存、抗BP180>72 U/mL或抗BP230>3 U/mL与死亡风险显著升高相关。

核心结论

  • 该研究为意大利首个全国性回顾性研究,调查了大疱性类天疱疮患者的死亡率和预后因素。
  • 基于简单风险因素(年龄、多病共存、保类固醇药物、泼尼松使用和疾病严重程度)联合两种临床常规检测的生物标志物(抗BP230和抗BP180自身抗体)的风险预测规则,在该病大系列患者中预测死亡率准确度约80%。

研究设计与样本

  • 回顾性多中心研究,纳入2005至2020年意大利12个中心诊断的大疱性类天疱疮患者,共572例。

主要发现

  • 粗死亡率为20.6%,年发病死亡率为5.9×100人年。
  • 1年、3年、5年和10年死亡率分别为3.2%、18.2%、27.4%和51.9%。
  • 多因素模型显示,年龄>78岁、多病共存、诊断时抗BP180自身抗体>72 U/mL或抗BP230>3 U/mL的患者死亡风险显著更高。
  • 联合纳入的变量预测死亡率的准确度(Harrel指数)为77%。

关键数值与推荐

  • 年龄>78岁、多病共存、抗BP180>72 U/mL或抗BP230>3 U/mL与死亡风险显著升高相关。
  • 基于年龄、多病共存、保类固醇药物、泼尼松使用、疾病严重程度及抗BP230和抗BP180自身抗体的风险预测规则预测死亡率准确度约80%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Bullous pemphigoid is the most common autoimmune bullous dermatosis. In recent years several studies have tried to identify the main factors of the disease related with an increased risk of death. The aim of this multicenter Italian study was to assess the risk score of death considering epidemiologic, clinical, immunological, and therapeutic factors in a cohort of patients affected by bullous pemphigoid and try to identify the cumulative survival up to 120 months. METHODS: We retrospectively reviewed the medical records of patients with bullous pemphigoid who were diagnosed between 2005 and 2020 in the 12 Italian centers. Data collected included sex, age at the time of diagnosis, laboratory findings, severity of disease, time at death/censoring, treatment, and multimorbidity. RESULTS: A total of 572 patients were included in the study. The crude mortality rate was 20.6%, with an incidence mortality rate of 5.9 × 100 person/year. The mortality rate at 1, 3, 5, and 10 years was 3.2%, 18.2%, 27.4% and 51.9%, respectively. Multivariate model results showed that the risk of death was significantly higher in patients older than 78 years, in presence of multimorbidity, anti-BP180 autoantibodies >72 U/mL, or anti-BP230 > 3 U/mL at diagnosis. The variables jointly included provided an accuracy (Harrel's Index) of 77% for predicting mortality. CONCLUSION: This study represents the first nationwide Italian study to have retrospectively investigated the mortality rates and prognostic factors in patients with bullous pemphigoid. A novel finding emerged in our study is that a risk prediction rule based on simple risk factors (age, multimorbidity, steroid-sparing drugs, prednisone use, and disease severity) jointly considered with two biomarkers routinely measured in clinical practice (anti-BP230 and anti-BP180 autoantibodies) provided about 80% accuracy for predicting mortality in large series of patients with this disease.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bardazzi F, Filippi F, Chessa MA, et al. Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study. J Eur Acad Dermatol Venereol. 2022. PMID: 35857348. doi:10.1111/jdv.18441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。